# SB17170 Phase 2 Trial in IPF Patients

> **NCT06747923** · PHASE2 · RECRUITING · sponsor: **SPARK Biopharma** · enrollment: 30 (estimated)

## Conditions studied

- IPF
- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** SB17170
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06747923
- **Lead sponsor:** SPARK Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-27
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06747923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06747923, "SB17170 Phase 2 Trial in IPF Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06747923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*